Valuation: Memphasys Limited

Market Cap 20.07M 14.29M 12.25M 11.44M 10.5M 19.74M 1.37B 135M 52.87M 685M 53.64M 52.47M 2.26B P/E 2024
-2.18x
P/E 2025 -1.57x
Enterprise Value 24.97M 17.78M 15.25M 14.24M 13.06M 24.57M 1.7B 168M 65.79M 852M 66.75M 65.3M 2.82B EV / Sales 2024
13,037,852x
EV / Sales 2025 24,365,123x
Free-Float
70.43%
Yield 2024 *
-
Yield 2025 -
1 day-14.29%
1 week-14.29%
Current month-20.00%
1 month-25.00%
3 months+50.00%
Current year-14.29%
1 week 0.01
Extreme 0.006
0.01
1 month 0.01
Extreme 0.006
0.01
Current year 0
Extreme 0.004
0.01
1 year 0
Extreme 0.002999
0.01
3 years 0
Extreme 0.002999
0.02
5 years 0
Extreme 0.002999
0.12
10 years 0
Extreme 0.002999
0.16
Manager TitleAgeSince
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 2021-06-30
Corporate Secretary - 2025-10-07
Director TitleAgeSince
Director/Board Member - 2018-06-06
Director/Board Member - 2025-10-19
Chairman - 2026-05-18
Date Insider Type Main position Quantity % Market Cap.
1/2/23 Buy

Director

1,400,000 0.1459%
1/2/23 Buy

Chief Executive Officer

392,500 0.0409%
1/24/22 Sell

Director

1,350,000 0.1704%
Change 5-day change 1-year change 3-year change Capi.($)
-14.29%-14.29%+50.00%-60.00% 13.14M
+4.16%+1.75%+23.13%+15.24% 218B
+5.97%+2.77%-0.33%-15.87% 140B
+1.67%-0.88%-17.00%+39.09% 138B
+3.05%+1.15%-49.87%+3.63% 73.14B
+1.43%-0.83%+16.91%+20.50% 52.44B
+1.32%+2.43%-16.15%-12.15% 50.85B
+4.70%+4.84%+29.39%+30.32% 41.92B
+3.64%-0.07%+39.67%+54.01% 39.42B
+2.74%+3.24%+0.88%+9.16% 32.81B
Average +1.23%+0.47%+7.66%+8.39% 78.69B
Weighted average by Cap. +3.32%+1.29%+2.40%+13.87%

Financials

2024 2025
Net sales 1.09 0.78 0.67 0.62 0.57 1.07 74.16 7.33 2.87 37.19 2.91 2.85 122.97 0.53 0.38 0.32 0.3 0.28 0.52 35.85 3.55 1.39 17.98 1.41 1.38 59.45
Net income -4.44M -3.16M -2.71M -2.53M -2.32M -4.37M -302M -29.89M -11.7M -152M -11.87M -11.62M -501M -5.04M -3.59M -3.08M -2.87M -2.64M -4.96M -343M -33.91M -13.28M -172M -13.47M -13.18M -569M
Net Debt 4.53M 3.23M 2.77M 2.58M 2.37M 4.46M 308M 30.49M 11.94M 155M 12.11M 11.85M 511M 4.9M 3.49M 2.99M 2.8M 2.57M 4.82M 334M 33M 12.92M 167M 13.11M 12.82M 553M
Logo Memphasys Limited
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.
Employees
24
Date Price Change Volume
26-08-17 A$0.006000 -14.29% 402,625
26-08-12 A$0.007000 +16.67% 409,981
26-08-11 A$0.006000 -7.69% 8,462,438